Why Aptevo (APVO) Shares Are Jumping Today - Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics Inc APVO announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve Acute Myeloid Leukemia (AML) patients.
The data also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.
Clinical activity was observed in both monotherapy and combination cohorts.
CRS was observed in fewer than one-quarter of patients within the safety population and, in most cases, was mild or moderate (grade 1 or 2) and manageable.
In the Phase 1b trial cohort 2, 16 response-evaluable patients received the combination therapy of venetoclax and azacitidine with APVO436, and 75% experienced clinical benefit.
100% of patients in this cohort who had not received venetoclax previously experienced clinical benefit.
Aptevo plans to initiate a Phase 2 trial in the second half of 2023 to further evaluate APVO436 in combination with venetoclax and azacitidine among frontline and relapsed/refractory AML patients who are venetoclax treatment naïve.
Price Action: APVO shares are up 65% at $5.66 on the last check Monday.

Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate